In the real‐world practice, we often use hot spot analysis, such as Roche Cobas V2, rather than an NGS to detect EGFR mutations at both lung cancer diagnosis, and resistance to an EGFR‐TKI. This evidence concerns the gene EGFR and lung carcinoma.